Hosted on MSN

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...
The Globe and Mail

Recursion Pharmaceuticals’ Earnings Call Highlights Progress and Challenges

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The recent earnings call for Recursion ...
Seeking Alpha

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and ...
Nasdaq

Recursion Pharmaceuticals call volume above normal and directionally bullish

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 5,540 calls trading, 2x expected, and implied vol increasing over 2 points to 75.26%. Jan-27 5 calls and Nov-24 8 calls are the ...
Investing

Earnings call transcript: Recursion Pharmaceuticals Q1 2025 results miss estimates

Recursion Pharmaceuticals Inc. (RXRX) reported its Q1 2025 financial results, revealing a slight miss on both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.5 against ...
Yahoo Finance

Recursion Pharmaceuticals, Inc. (RXRX) Q1 FY2025 earnings call transcript

Earnings call Recursion Pharmaceuticals reported a strategic pipeline overhaul, discontinuing lower-priority programs and focusing on five high-potential clinical and preclinical assets. The company ...